Gregory R Wiedman

Title: Gregory R Wiedman: Innovator in Antifungal Peptides

Introduction

Gregory R Wiedman is a notable inventor based in New Milford, NJ (US). He has made significant contributions to the field of antifungal research, particularly through his innovative work on antifungal peptides. His research focuses on developing compounds that enhance the efficacy of existing antifungal treatments.

Latest Patents

Wiedman holds a patent for "Antifungal peptides, compounds including the same, and methods of use thereof." This patent describes an antifungal peptide that targets P4-ATPase function, synthesized based on the Cdc50 loop region. The research identified peptides that sensitize caspofungin by blocking flippase function. Notably, myristylated peptides based on the 'AS15 sequence' were found to be effective at high concentrations. A modified peptide, “AW9-Ma,” demonstrated a minimum inhibitory concentration (MIC) of 64 μg/mL against H99 wild type and a fractional inhibitory concentration (FIC) index value of 0.5 when used in conjunction with caspofungin. The AW9-Ma peptide showed that the wild type was highly sensitive to caspofungin with a MIC of 4 μg/mL, similar to the cdc50Δ mutant. Further assays using flow cytometry confirmed the inhibition of lipid flippase enzyme activity and significant accumulation of phosphatidylserine on the cell surface. The peptide was also confirmed to co-localize with mCherry-tagged P4-ATPase protein Apt1. Modification studies indicated that two lysine residues on the peptide are likely responsible for its interaction with P4-ATPase, which is critical for its antifungal activity.

Career Highlights

Throughout his career, Gregory R Wiedman has worked at prestigious institutions, including Seton Hall University and Rutgers, The State University of New Jersey. His research has contributed to advancements in antifungal therapies, showcasing his commitment to improving health outcomes through innovation.

Collaborations

Wiedman has collaborated with notable colleagues, including Robert J Tancer and Chaoyang Xue. These collaborations have further enriched his research and contributed to the development of effective antifungal treatments.

Conclusion

Gregory R Wiedman's work in the field of antifungal peptides represents a significant advancement in medical research. His